Scinai Immunotherapeutics (SCNI) News Today $3.02 +0.09 (+3.07%) (As of 12:05 PM ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Scinai Immunotherapeutics (NASDAQ: SCNI) to Spotlight I&I Pipeline, CDMO Services at BIO-Europe 2024October 31, 2024 | theglobeandmail.comScinai Leadership to Showcase Company's cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024October 31, 2024 | prnewswire.comScinai Immunotherapeutics (NASDAQ:SCNI) Stock, Short Interest ReportOctober 6, 2024 | benzinga.comScinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH AntibodiesSeptember 16, 2024 | prnewswire.comScinai Immunotherapeutics (NASDAQ: SCNI) CEO Featured on Latest Episode of BioMedWire PodcastSeptember 11, 2024 | theglobeandmail.comBioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) CEO Featured Guest on Latest Episode of BioMedWire PodcastSeptember 10, 2024 | msn.comIBN Announces Latest Episode of The BioMedWire Podcast featuring Amir Reichman, CEO of Scinai Immunotherapeutics Ltd.September 9, 2024 | globenewswire.comSCINAI IMM.ADS/4000 IL-01 (2F5.F)September 8, 2024 | sg.finance.yahoo.comScinai Immunotherapeutics Ltd.: Scinai Regains Full Compliance with Nasdaq Listing RequirementsAugust 29, 2024 | finanznachrichten.deScinai Regains Full Compliance with Nasdaq Listing RequirementsAugust 29, 2024 | prnewswire.comSCINAI IMM.ADS/4000 IL-01 (2F5.BE)August 28, 2024 | finance.yahoo.comScinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000August 21, 2024 | prnewswire.comScinai Immunotherapeutics Ltd. (SCNI) Q2 2024 Earnings Call TranscriptAugust 20, 2024 | seekingalpha.comScinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing ShareholderAugust 20, 2024 | prnewswire.com2F5.SG,0P0001KEDB,0 (2F5.SG)August 16, 2024 | finance.yahoo.comSCNI Stock Earnings: Scinai Immunotherapeutics Reported Results for Q2 2024August 15, 2024 | investorplace.comScinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23August 15, 2024 | prnewswire.comScinai Announces Signing of Loan Restructuring Agreement with European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common EquityAugust 13, 2024 | prnewswire.comScinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAbJuly 23, 2024 | prnewswire.comWhy Is Scinai Immunotherapeutics (SCNI) Stock Up 56% Today?July 15, 2024 | investorplace.comScinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept psoriatic human skin modelJuly 15, 2024 | prnewswire.comScinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to EquityJuly 8, 2024 | prnewswire.comScinai Immunotherapeutics Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing RequirementsJuly 3, 2024 | prnewswire.comSCNI Stock Earnings: Scinai Immunotherapeutics Reported Results for Q1 2024July 2, 2024 | investorplace.comScinai Publishes Q1 2024 Financial Results and Provides Business UpdateJuly 2, 2024 | prnewswire.comWhy Is Scinai Immunotherapeutics (SCNI) Stock Up 88% Today?June 17, 2024 | investorplace.comScinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity.June 13, 2024 | prnewswire.comScinai Immunotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Continues to Work with the European Investment Bank to Convert Loan to Equity to Regain Compliance with Nasdaq Minimum Shareholders' Equity RequirementJune 7, 2024 | prnewswire.comSCNI Stock Earnings: Scinai Immunotherapeutics Reported Results for Q4 2023June 3, 2024 | investorplace.comScinai Immunotherapeutics Announces Receipt of a Nasdaq Staff Determination Letter Regarding Shareholders' Equity listing requirements and Hearing to Present a Plan for Regaining ComplianceMay 24, 2024 | prnewswire.comScinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business UpdateMay 15, 2024 | prnewswire.comScinai Immunotherapeutics Ltd.: Scinai Immunotherapeutics Announces Receipt of Nasdaq Delisting Notification and AppealMay 6, 2024 | finanznachrichten.deScinai Immunotherapeutics Announces Receipt of Nasdaq Delisting Notification and AppealMay 6, 2024 | prnewswire.comScinai Immunotherapeutics Ltd ADR SCNIApril 17, 2024 | morningstar.comScinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMGApril 10, 2024 | prnewswire.comScinai Immunotherapeutics (NASDAQ: SCNI), Scinai Bioservices Enter MSA with Ayana PharmaApril 9, 2024 | theglobeandmail.comScinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing ServicesApril 8, 2024 | prnewswire.comScinai leadership to attend BIO-Europe Spring 2024March 12, 2024 | finance.yahoo.comScinai to showcase its cGMP biologics CDMO and innovative NanoAb pipeline at MIXiii 2024February 29, 2024 | prnewswire.comScinai Welcomes Liat Halpert as Head of Business Development and SalesFebruary 13, 2024 | finance.yahoo.comScinai Immunotherapeutics Ltd ADRFebruary 3, 2024 | morningstar.comScinai Immunotherapeutics Congratulates its Co-Lead Scientific Research Collaborator Dirk Görlich on Louis-Jeantet PrizeJanuary 25, 2024 | finance.yahoo.comScinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross ProceedsJanuary 4, 2024 | finance.yahoo.comScinai Immunotherapeutics Ltd.: Scinai Immunotherapeutics CEO Issues Letter to ShareholdersJanuary 4, 2024 | finanznachrichten.deScinai Immunotherapeutics CEO Issues Letter to ShareholdersJanuary 4, 2024 | finance.yahoo.comScinai Immunotherapeutics to raise $1.7M through exercise of outstanding warrantsDecember 29, 2023 | msn.comScinai Immunotherapeutics Announces Exercise of Outstanding Warrants for $1.69 Million in Gross ProceedsDecember 29, 2023 | finance.yahoo.comScinai (NASDAQ: SCNI) to Host Analyst and Investor Webinar on January 9December 27, 2023 | finance.yahoo.comScinai Immunotherapeutics Ltd. ADRDecember 23, 2023 | wsj.comScinai Immunotherapeutics Ltd ADR (SCNI)December 21, 2023 | investing.com Get Scinai Immunotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SCNI and its competitors with MarketBeat's FREE daily newsletter. Email Address Tesla Execs are Freaking Out (Ad)It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss. Click here to get the details. SCNI Media Mentions By Week SCNI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SCNI News Sentiment▼0.000.47▲Average Medical News Sentiment SCNI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SCNI Articles This Week▼01▲SCNI Articles Average Week Get Scinai Immunotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SCNI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Organovo News Aptose Biosciences News Creative Medical Technology News BioCardia News Fresh Tracks Therapeutics News Genetic Technologies News Gritstone bio News Palisade Bio News Chromocell Therapeutics News Titan Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SCNI) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scinai Immunotherapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Scinai Immunotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
